Inadequate Glycemic Control in Type 1 Diabetes: Why Can We Not Achieve Glycemic Targets?

This interactive web activity provides an update on the need for non-insulin adjunctive treatments for type 1 diabetes (T1D). The activity reviews the challenges of managing glycemic levels in people with T1D, limitations of insulin therapy, and need for effective adjunctive treatments.

Target Audience

This activity has been designed to meet the educational needs of endocrinologists and other healthcare professionals involved in the diagnosis, treatment, or management of patients with T1D.

Educational Objectives 

Upon completion of this activity, participants will be better able to do the following:

  1. Review the potential barriers to care, associated risks, and impact of unachieved glycemic control in patients with Type 1 diabetes.
  2. Describe currently available adjunctive options for glycemic control.
  3. Discuss the mechanisms of action and potential synergistic effects of new and emerging sodium-glucose cotransporter (SGLT) 1 and 2 inhibitors.

Faculty

Satish K. Garg, MD
Editor-in-Chief, Diabetes Technology & Therapeutics
Professor of Medicine and Pediatrics
Barbara Davis Center for Diabetes
University of Colorado Denver
Denver, Colorado

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of these educational activities.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of these CME activities:

Faculty

Relationship Identified With:

Satish K. Garg, MD

Consultant/Advisor: Eli Lilly and Company, Medtronic, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Lexicon Pharmaceuticals, Inc., Novo Nordisk A/S, Sanofi, Mannkind Corporation, Senseonics, and Zealand Pharma A/S

Grant/Research Support*: Animas Corporation, DarioHealth Corp., Dexcom, Eli Lilly and Company, JDRF, Lexicon Pharmaceuticals, Inc., Medtronic, Merck & Co., Inc., National Cancer Institute, National Institute of Diabetes and Digestive and Kidney Diseases Health Information Center, Novo Nordisk A/S, T1D Exchange,  and Sanofi

*All Research grants through University of Colorado Denver

Non-faculty: Sandy Breslow, Alison Kemp, Bernard M. Abrams, MD, Marilu Kelly, MSN, RN, CNE, Louis Settembrino, CHCP, and Christina M. Ohnsman, MD hereby state that neither they nor their spouse/life partner have had any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Financial Support

This activity has been supported by an independent educational grant from Sanofi US and Lexicon Pharmaceuticals, Inc.

Provider Information

Jointly provided by the Elsevier Office of Continuing Medical Education, Elsevier, and Catalyst Medical Education, LLC.

 

CME Credit (Physicians)

These activities have been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Catalyst Medical Education, LLC. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in each activity.

CE CREDITS (NURSING)

This continuing nursing education activity, provided by Elsevier, awards 0.75 contact hour for nurses.

Elsevier is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Elsevier is provider approved by the Florida Board of Nursing, Provider #50-4681, and the California Board of Registered Nursing, Provider #CEP 3257 for 0.75 contact hour.

CME Inquiries/Special Needs

For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.


Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, Catalyst Medical Education, LLC., and Sanofi US and Lexicon Pharmaceuticals, Inc. do not recommend the use of any agent outside of the labeled indications.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Course summary
Available credit: 
  • 0.75 AMA PRA Category 1 Credit(s)™
  • 0.75 Nursing Contact Hours
  • 0.75 Non-physician
Course opens: 
10/31/2018
Course expires: 
10/30/2019
Rating: 
0

Available Credit

  • 0.75 AMA PRA Category 1 Credit(s)™
  • 0.75 Nursing Contact Hours
  • 0.75 Non-physician

Accreditation Period

Course opens: 
10/31/2018
Course expires: 
10/30/2019
Please login or register to take this course.